TRADING UPDATES: Tungsten West scales up fundraise amid strong demand
6th Feb 2026 21:55
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of several US data releases due in the afternoon. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - GENinCode PLC on Wednesday said it has entered a commercial agreement with a Mexican healthcare provider for the distribution of its polygenic risk score test for heart health. Read More
GENinCode PLC - Oxford-based genetic testing company and Thermo Fisher Scientific Inc - Waltham, Massachusetts-based life science technology firm - Thermo Fisher Scientific to sell, distribute and manufacture GENinCode's CARDIO inCode-Score Polygenic Risk Score test for the prediction and prevention of coronary heart disease. On Thursday, the test was approved by the New York Department of Health, leading shares higher. Discussions with the US Food and Drug Administration are ongoing, and GENinCode expects to submit additional data to complete its De Novo assessment application in the first quarter of 2026. The Thermo Fisher agreement covers sale and distribution across the US and Europe, Middle East and Africa. Prior to US FDA approval, laboratories will have access to CARDIO inCode-Score as a lab developed test for the prevention of heart disease. Following approval, the collaboration will extend to manufacturing and sale of the device to laboratories and test centres across the US. The approach will be similar in the EMEA market. Read More
(Alliance News) - Stock prices in London were higher at midday on Thursday, though data showed that in November UK construction activity fell at the fastest pace since the pandemic. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More
(Alliance News) - GENinCode PLC on Wednesday said its polygenic risk score test for heart health has been approved by the New York Department of Health as it advances its US Food & Drug Administration assessment. Read More
(Alliance News) - Stock prices in London were lower at midday on Wednesday, as the FTSE 100 failed to benefit from a rally among European peers. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - GENinCode PLC on Wednesday said it "knows no reason" for recent fluctuation of its share price, reaffirming guidance published in August. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
GENinCode PLC - Oxford, England-based genetics testing company - Provides update on its US Food and Drug Administration submission for De Novo. "While the number of the outstanding deficiencies has been reduced, the review upheld the FDA's prior view that there remains certain outstanding elements, including further information in relation to clinical validation." The FDA had determined in April that certain outstanding elements in De Novo needed to be addressed, including deficiencies in relation to clinical validation. Read More
(Corrects the 4Global adjusted Ebitda forecast for financial 2025.) Read More
(Alliance News) - GENinCode PLC shares soared on Wednesday as it reported increased revenue and said it expects a further "significant increase" during 2025. Read More